Hatchtech is submitting its Xeglyze lice treatment to the FDA for approval and has signed a commercialisation agreement with Dr. Reddy’s.
The Australian company is submitting its new drug application for Xeglyze to the FDA following successful clinical trials. They have also concluded a commercialisation deal with Dr. Reddy’s Laboratories worth up to $279 million, including an up-front fee of $10 million.
The terms of the deal grant Dr Reddy’s distribution rights for the US, Canada, and India among others. This is the result of a process to find a commercial US partner to market Xeglyze announced in March 2015.